Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: Synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5630-5640

  Koch, Pierre ^a   Bäuerlein, Christiane ^a   Jank, Hartmut ^a   Laufer, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHATE; RIBOSE;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; IC 50; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROGEN BONDING; IMIDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATES; RIBOSE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 52449118840     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800373t     Document Type: Article

References (24)

1. Feldmann, M.; Brennan, F. M.; Maini, R. N. Rheumatoid arthritis. Cell 1996, 85, 307-310.
2. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol. Ther. 1999, 82, 389-397.
3. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discovery 2003, 2, 717-726.
4. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
5. Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38a protein. Curr. Med. Chem. 2005, 12, 2979-2994.
6. Feldmann, M. Pathogenesis of arthritis: recent research progress. Nat. Immunol. 2001, 2, 771-773.
7. Kaminska, B. MAPK signalling pathways as molecular targets for antiinflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 2005, 1754, 253-262.
8. Wagner, G.; Laufer, S. Small molecular anti-cykotine agents. Med. Res. Rev. 2006, 26, 1-62.
9. Tong, L.; Pav, S.; White, D. M.; Rogers, S.; Crane, K. M.; Cywin, C. L.; Brown, M. L.; Pargellis, C. A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 1991, 4, 311-316.
10. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
11. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423-431.
12. Vogtherr, M.; Saxena, K.; Hoelder, S.; Grimme, S.; Betz, M.; Schieborr, U.; Pescatore, B.; Robin, M.; Delarbre, L.; Langer, T.; Wendt, K. U.; Schwalbe, H. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew. Chem., Int. Ed. 2006, 45, 993-997.
13. Adams, J. L.; Boehm, J. C.; Kassis, S.; Gorycki, P. D.; Webb, E. F.; Hall, R.; Sorenson, M.; Lee, J. C.; Ayrton, A.; Griswold, D. E.; Gallagher, T. F. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. 1998, 8, 3111-3116.
14. Peifer, C.; Wagner, G.; Laufer, S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2006, 6, 113-149.
15. Laufer, S. A.; Striegel, H. G.; Wagner, G. K. Imidazole inhibitors of cytokine release: probing substituents in the 2 position. J. Med. Chem. 2002, 45, 4695-4705.
16. Laufer, S. A.; Wagner, G. K.; Kotschenreuther, D. A.; Albrecht, W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J. Med. Chem. 2003, 46, 3230-3244.
17. Lantos, I.; Gombatz, K.; McGuire, M.; Pridgen, L.; Remich, J.; Shilcrat, S. Synthetic and mechanistic studies on the preparation of pyridyl-substituted imidazothiazoles. J. Org. Chem. 1988, 53, 4223-4227.
18. Neber, P. W.; Burgard, A. Course of the reaction in a new type of rearrangement of ketoximes.III. Ann. 1932, 493, 281-294.
19. Laufer, S.; Wagner, G.; Kotschenreuther, D. Ones, thiones, and N-oxides: an exercise in imidazole chemistry. Angew. Chem., Int. Ed. 2002, 41, 2290-2293.
20. Laufer, S.; Koch, P. Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. Org. Biomol. Chem. 2008, 6, 437-439.
21. Wolfe, J. P.; Wagaw, S.; Marcoux, J. F.; Buchwald, S. L. Rational development of practical catalysts for aromatic carbon-nitrogen bond formation. Acc. Chem. Res. 1998, 31, 805-818.
22. Laufer, S.; Thuma, S.; Peifer, C.; Greim, C.; Herweh, Y.; Albrecht, A.; Dehner, F. An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Anal. Biochem. 2005, 344, 135-137.
23. Laufer, S. A.; Hauser, D. R. J.; Liedtke, A. J. Regiospecific and highly flexible synthesis of 1,4,5-trisubstituted 2-sulfanylimidazoles from structurally diverse ethanone precursors. Synthesis 2008, 253-266.
24. Koch, P.; Bäuerlein, C.; Schollmeyer, D.; Laufer, S. Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfanyl] butanoate. Acta Crystallogr., Sect. E: Struct. Rep. Online 2008, E64, o1183-o1184.